Skip to main content
OpenTrials
Completed

NCT Number: NCT01216033

Exploratory Study of Breast Cancer With ABY025

The aim is to study if breast cancer metastases accumulate the newly developed HER2 binding molecule 111-In-ABY025 and if that shows whether the metastases express HER2.

Completed

Looking for future studies?

Notify Me

Key information

Age range

20 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Phase 1 / Phase 2

Primary location

Akademiska Hospital

Uppsala, Uppland, SE75185, Sweden

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • female age >20 years
  • one or more known metastases localizations

Exclusion criteria

  • other critical disease than breast cancer
  • age ≤ 20 years

Treatment and study plan

111-In-ABY-025

Drug

Intravenous injection of the agent

Primary outcomes

  1. Imaging of metastases

    Time frame: One year

    Imaging of breast cancer metastases using 111-In-ABY015 for SPECT

Secondary outcomes

  1. Can the new molecule be used for imaging in extended studies

    Time frame: October 2010 - June 2011

Sponsors and collaborators

Lead sponsor

Biomedical Radiation Sciences

Other

Collaborators

  • Swedish Cancer Society

Registry information

Official study title

An Exploratory Study to Evaluate the Distribution of [111In]ABY-025 Uptake for SPECT Imaging in Subjects With Metastatic Breast Cancer

Acronym: ABY0125

Important dates

Study start
2010
Primary completion
2011
Study completion
2011
First posted
Oct 7, 2010
Registry last updated
Apr 15, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.